Decentralized Trials: 2025 Guide to Design, Tech & FDA

Decentralized trials are revolutionizing how medical research gets done. Instead of asking patients to constantly travel to a central hospital, this modern approach brings the study to them, using technology and local resources. It’s a shift that makes clinical trials more accessible, efficient, and patient friendly.

This guide breaks down everything you need to know about decentralized trials, from the core concepts to the nitty gritty of design, technology, and regulation.

The Fundamentals of Decentralized Trials

Let’s start with the basics. What exactly are decentralized trials, and what different forms can they take?

What is a Decentralized Clinical Trial?

A decentralized clinical trial (DCT) is a study where some or all trial activities happen outside of traditional research sites. Instead, these activities occur where the patient is, whether that’s at home, a local clinic, or through a virtual visit. The U.S. Food and Drug Administration (FDA) notes this approach makes trials more accessible and can increase participant diversity.

The momentum for this model grew significantly during the COVID-19 pandemic. To keep research going, sponsors embraced telemedicine and home health visits. This trend has continued, with an estimated 1,300 clinical trials with decentralized elements launching in 2022, a 28% increase from the year before. Companies like Curebase are built on this principle, aiming to make research participation possible for any patient, anywhere through our decentralized clinical trials model.

Hybrid vs. Fully Decentralized Trial Models

Decentralized trials are not an all or nothing concept. They exist on a spectrum.

Fully Decentralized Trials: In this model, every single activity is remote. Participants might use an app to report data, have video calls with investigators, and get blood drawn by a mobile nurse at home. There are no visits to a central clinic.
Hybrid Trials: This is the most common approach today. A hybrid trial blends remote activities with some traditional site visits. For example, a participant might have their initial screening at a clinic but complete all follow up visits from home using telehealth.

Most studies today are hybrid, allowing sponsors to choose which elements to decentralize based on the study’s needs, patient safety, and practicality. The key is flexibility.

Designing and Planning Your Study

A successful decentralized trial starts with a smart plan. This involves thinking differently about everything from the protocol itself to how you find and support participants.

DCT Design and Conduct

Designing a decentralized trial requires careful planning to ensure remote processes are scientifically sound and regulatorily compliant. You need to decide which activities can realistically move away from the central site. For instance, can a lab test be done at a local facility near the patient? Can a follow up visit happen over a video call?

Engaging all stakeholders (sponsors, investigators, and even patient groups) early in the design process is crucial. The protocol needs to clearly map out how data will flow and who is responsible for each remote task. The goal is a “fit for purpose” design, meaning you only use decentralized methods that truly serve the study’s objectives.

DCT Feasibility Assessment

Before you commit to a model, a DCT feasibility assessment helps determine which decentralized elements will work for your specific study. Not every trial can be fully remote. This evaluation answers critical questions:

Can the study’s main goals be measured with remote technology?
Is the patient population comfortable using digital tools like apps or video calls?
Does the investigational product require special handling that makes at home use difficult?

This assessment often leads to a hybrid design. It helps identify opportunities (like faster enrollment) and plan for necessary resources. Partnering with a DCT expert early can help answer the question, “Can we do this, and if so, how?”

Logistics and Site Planning for Decentralized Trials

Effective logistics are the backbone of a successful DCT. Planning must account for a distributed network of patients, local healthcare providers, and home health staff. Precise coordination is needed to manage everything from direct to patient drug deliveries to scheduling mobile nurse visits. Key logistical areas include:

Vendor Selection and Management: Choosing the right partners for technology, shipping, and home health services is critical. Sponsors need to ensure vendors are fully qualified and that data flows seamlessly between all parties.
Supply Chain Coordination: A robust plan is needed for shipping supplies, investigational products, and biological samples. This includes managing temperature controlled shipments and ensuring chain of custody.
Local Provider Training: When local clinics or pharmacies are involved, they must be trained on the protocol and their specific responsibilities to ensure data consistency and quality.

Recruitment and Enrollment Strategy

Because decentralized trials aren’t tied to a specific location, recruitment can be a much broader, digital effort. Sponsors can reach potential participants across huge geographic areas using social media campaigns, online communities, and digital advertising as part of a modern clinical trial patient recruitment strategy.

This strategy can dramatically speed up enrollment and improve diversity. One virtual trial, for example, enrolled 850 patients over 70% faster than projected by using nationwide digital outreach. In another example, Walgreens partnered with Freenome and used the Curebase platform to reach diverse populations through text, email, and even in person consultations at local pharmacies for a cancer screening study. This community based approach works. A Tufts CSDD analysis found that DCTs enrolled a higher percentage of minority participants compared to traditional trials.

Electronic Informed Consent (eConsent)

Electronic informed consent, or eConsent, is the process of getting a participant’s permission to join a study using digital tools instead of paper forms. Participants can review study information on a tablet or smartphone, often with interactive features like videos or quizzes to improve understanding. They then provide their consent with an electronic signature.

Research suggests eConsent can improve how well participants understand trial details. The FDA supports its use as long as it meets regulatory standards for electronic records (like 21 CFR Part 11) and protects patient privacy. It’s a key tool that allows for remote enrollment, broader reach, and better participant engagement from the very start.

Participant Training and Orientation

In a decentralized trial, participants take on a more active role, so proper training is essential. Participant orientation involves teaching patients how to use the required tools and follow remote procedures. This can include:

Live virtual walkthroughs of the study app.
Tutorial videos for using a home blood pressure monitor.
Clear user guides and access to a 24/7 helpdesk.

The goal is to make participants feel confident and comfortable. When they know how to use the technology and what is expected of them, they are more likely to stick with the trial and provide high quality data, especially with robust participant engagement tools.

The Technology and Operations That Power DCTs

Technology is the engine of any decentralized trial. From apps and wearables to virtual visits and local healthcare partnerships, a complex operational ecosystem works behind the scenes.

Digital Health Technology for Remote Data Acquisition

This category includes all the software and devices that collect data from participants outside a clinic. Common tools include:

Smartphone Apps: For electronic patient reported outcomes (ePRO) and electronic diaries.
Wearable Sensors: Fitness trackers, smartwatches, and continuous glucose monitors that capture real time health metrics.
Remote Monitoring Devices: Bluetooth enabled blood pressure cuffs, scales, or ECG patches.

These technologies provide a continuous stream of real world data, offering a much richer picture of a patient’s health than occasional clinic visits. In fact, experts predicted that by 2025, half of all clinical trials could include data from wearable sensors.

Wearable Endpoint Capture

Wearable endpoint capture is the specific use of wearable devices to measure a trial’s primary outcomes. For example, a smartwatch could track tremor frequency in a Parkinson’s study, or a fitness band could measure daily activity levels to assess a new mobility treatment.

This method provides objective, high frequency data that is less burdensome for patients to collect. The data from these devices must be validated to ensure it is accurate and reliable enough to serve as an official study endpoint. The FDA is increasingly open to endpoints captured by wearables, recognizing their power to measure meaningful outcomes in a patient’s daily life.

Electronic Systems Used in DCTs

Decentralized trials run on a suite of integrated electronic systems that manage data, communication, and oversight. These often include:

Electronic Data Capture (EDC): The central database for all trial data.
ePRO/eCOA platforms: Apps for patient reported outcomes.
eConsent Systems: For managing the digital consent process.
Telehealth Platforms: For conducting virtual visits.
Dashboards and Portals: For investigators and sponsors to monitor progress in real time.

Many sponsors are moving toward unified platforms that combine these functions into a single, seamless system. An integrated solution, like the AI native platform from Curebase, provides end to end capabilities that simplify workflows and avoid data silos.

Remote Clinical Trial Visit and Telehealth Use

A remote clinical trial visit is any study check in that happens without the participant traveling to the site. This is usually done through telehealth, using secure video conferencing or phone calls. These virtual visits can be used for routine follow ups, symptom checks, or medication reviews.

Telehealth is the backbone of remote patient interaction. It saves patients time and money and has been shown to reduce participant burden by around 67%. While it introduces some logistical considerations, like ensuring clinicians are licensed in the participant’s state, its benefits in expanding a trial’s reach are undeniable. Today, about 71% of trial sponsors have implemented some form of telemedicine.

Local Healthcare Provider and Home Health Involvement

Decentralized trials often leverage existing healthcare infrastructure by involving local providers. This means a participant’s primary care doctor or a nearby clinic could perform certain study tasks, like a physical exam or a blood draw.

Local Healthcare Provider Involvement: This approach makes participation more convenient and comfortable for patients. For instance, Walgreens has acted as a community based research site, with its pharmacists helping to recruit patients and conduct trial activities in their stores.
Home Health Visit: This is when a healthcare professional, like a nurse or phlebotomist, comes to the participant’s home to conduct study procedures. This is invaluable for tasks like blood draws, administering injections, or collecting samples, making it possible for patients with limited mobility to participate.

Managing Investigational Products in a Decentralized Model

Getting the study drug or device to participants safely and reliably is a critical logistical challenge in any decentralized trial.

Considerations for Drugs and Biologics

The FDA advises that the nature of an investigational product (IP) is a key factor in determining if it’s suitable for a DCT. For drugs and biologics, key considerations include:

Safety Profile: Products with a high risk safety profile or those in early development stages may require in person supervision.
Stability and Storage: Drugs with long shelf lives and good stability profiles are best suited for direct shipment to a participant’s home. Products requiring specialized temperature control present greater logistical challenges.
Administration: Complex administration procedures, such as intravenous infusions, may need to be done at a local clinic or by a home health nurse, whereas oral medications can often be self administered.

Considerations for Medical Devices

The approach for medical devices in DCTs depends heavily on the device itself.

Complexity and Risk: High risk devices that require professional oversight are less suitable for fully remote use. In contrast, devices designed for self use at home, such as some software as a medical device (SaMD) or wearable sensors, are a natural fit for DCTs.
Participant Training: For devices participants will use themselves, clear instructions and training are essential to ensure correct usage and data quality. This can be delivered through telehealth visits, videos, or user guides.
Data Transmission: The plan must include secure and reliable methods for transmitting data from the device to the central study database. Sponsors should ensure the technology is suitable for all participants.

Investigational Product Packaging and Direct to Patient Shipping

Direct to patient (DTP) shipments involve sending the IP from a pharmacy directly to a participant’s home. This method requires careful planning:

Packaging: The IP must be packaged to maintain its integrity, using temperature controlled containers and tamper evident seals when needed.
Shipping and Tracking: Specialty couriers with real time tracking and delivery confirmation are used to maintain a clear chain of custody.
Documentation: All shipment records must be meticulously maintained according to regulatory requirements.

Ensuring Quality, Safety, and Compliance

Even when a trial is remote, the standards for data quality, patient safety, and regulatory compliance remain as high as ever.

Data Reliability and Quality Monitoring

Sponsors use several strategies to ensure data collected remotely is reliable. Digital platforms have built in edit checks that can flag improbable entries in real time. Since data flows in instantly, monitors can spot trends or missing information quickly. Much of the source data in a DCT is the electronic record itself, which reduces the risk of human error from manual data transcription.

Electronic System and Software Validation

All electronic systems used in a clinical trial must be validated to prove they work as intended. This is a core requirement of regulations like 21 CFR Part 11. Validation involves:

Documenting Requirements: Clearly defining what the system needs to do.
Testing: Executing documented tests to confirm the system meets all requirements accurately and reliably.
Creating a Summary Report: Producing a final report that proves the system is fit for purpose.

Sponsors are responsible for ensuring all technology vendors, including software providers and their subcontractors, meet these validation standards.

Safety Monitoring and Adverse Event Reporting

Patient safety is monitored through proactive communication and remote tools. Participants may be given devices to track vital signs at home, with alerts programmed to notify the study team of any concerning readings. They are also trained to report any adverse events immediately through the study app or a 24/7 hotline. A clear safety monitoring plan is required by the FDA.

When an adverse event is reported, the investigator assesses it remotely, often via a telehealth call. The event is documented with the same rigor as in a traditional trial, and serious events are reported to regulatory bodies within the required timelines. This system of tech enabled vigilance and constant communication ensures a strong safety net around every participant.

Participant Privacy and Confidentiality

Protecting patient data is critical. Decentralized trial platforms use multiple layers of security, including:

Data Encryption: Protecting data both in transit and at rest.
Access Controls: Ensuring only authorized staff can view sensitive information.
De identification: Separating personal identifiers from clinical data.
Regulatory Compliance: Adhering to privacy laws like HIPAA and GDPR.

Roles and Responsibilities in a Decentralized Model

A decentralized trial involves a complex orchestra of people and organizations. Clear roles are essential for it to run smoothly.

The Sponsor and Investigator Roles

Sponsor Role: The sponsor is ultimately responsible for the entire study. In a DCT, this means orchestrating a more complex network of technology vendors and service providers. They must validate all digital platforms and maintain oversight of all remote activities, often using real time dashboards to monitor progress.
Investigator Role: The principal investigator (PI) remains responsible for participant safety and data integrity. They oversee the trial remotely, delegating tasks like blood draws or assessments to qualified local providers or mobile nurses. This delegation must be carefully documented, and the PI must maintain clear oversight through remote communication and data review.

IRB and FDA Oversight

IRB Oversight: An Institutional Review Board (IRB) still provides ethical oversight to protect participants. For multi state decentralized trials, a central IRB is often used. The IRB reviews all aspects of the study, including the eConsent process and the privacy protections for digital data.
FDA Oversight and Regulatory Requirements: The FDA applies the same regulations to decentralized trials as it does to traditional ones. In May 2023, the agency released draft guidance offering specific recommendations for conducting DCTs. The core message is that decentralization should never compromise data quality or patient safety.

Conclusion

Decentralized trials represent a fundamental shift toward a more patient centric and efficient model for clinical research. By leveraging technology, flexible site models, and community engagement, they break down geographical barriers and make it possible for more people to participate in the development of new medicines.

While they require careful planning and new operational workflows, the benefits are clear: faster enrollment, greater diversity, richer data, and a better experience for participants. As technology continues to evolve, decentralized trials will play an increasingly vital role in the future of healthcare innovation.

If you’re looking to harness the power of this modern approach, it’s crucial to partner with an expert in the field. Explore integrated eClinical software for decentralized trials that combine a powerful software platform with expert operational support.

Glossary of Key DCT Terms

Decentralized Clinical Trial (DCT): A clinical trial where some or all activities occur at locations other than a traditional research site, such as a participant’s home.
Direct to Patient (DTP): A model for shipping investigational products or other study supplies directly to a participant’s location.
eConsent: Electronic Informed Consent. A process where study information is presented digitally and participants provide consent using an electronic signature.
eCOA (Electronic Clinical Outcome Assessment): The electronic capture of measures that describe how a participant feels or functions during a trial.
EDC (Electronic Data Capture): A computerized system used to collect clinical data in an electronic format.
ePRO (Electronic Patient Reported Outcome): A type of eCOA where data is reported directly by the participant, typically through an app or web portal.
Hybrid Trial: A trial that combines elements of a traditional, site based model with decentralized components.
Investigational Product (IP): The drug, biologic, or device being tested in a clinical trial.
Telehealth: The use of digital communication technologies (like video calls) to provide healthcare and conduct trial visits remotely.

Frequently Asked Questions about Decentralized Trials

1. What is the main benefit of decentralized trials?
The primary benefit is making clinical trials more accessible to patients. By reducing or eliminating the need to travel to a specific site, DCTs can attract a more diverse group of participants from a wider geographic area, potentially speeding up recruitment.

2. Are decentralized trials less safe than traditional trials?
No. Patient safety remains the top priority. DCTs use a combination of remote monitoring technology, regular telehealth check ins, and 24/7 support lines to monitor participant health just as rigorously as traditional trials. All safety events are reported and managed according to strict regulatory standards.

3. How is data quality managed in a remote setting?
Data quality is managed through validated electronic systems with built in checks, real time monitoring by data managers, and robust training for participants. The direct capture of data electronically (eSource) often reduces the human errors associated with transcribing from paper, which can improve overall data accuracy.

4. Can any clinical trial be decentralized?
Not necessarily. A feasibility assessment is needed to determine if a trial is a good fit. Studies involving complex procedures that require specialized on site equipment or intensive in person monitoring may be better suited for a hybrid or traditional model.

5. What technology is essential for running decentralized trials?
Key technologies include a central electronic data capture (EDC) system, an ePRO/eCOA platform for patient reporting (usually via a mobile app), an eConsent solution, and a secure telehealth platform for virtual visits. Many successful DCTs use an integrated platform that combines all of these functions.

6. How do you ship study medication to patients’ homes?
Investigational products are sent via direct to patient (DTP) shipments using specialty couriers. The process involves temperature controlled packaging, real time tracking, and signature confirmation to ensure the product arrives safely and maintains its integrity.

7. Who oversees the ethics of a decentralized trial?
An Institutional Review Board (IRB) or an independent ethics committee provides ethical oversight, just as in a traditional trial. They review the protocol, consent forms (including eConsent), and all participant facing materials to ensure the rights and welfare of participants are protected.

8. Is the FDA supportive of decentralized trials?
Yes. The FDA has been very supportive, recognizing that DCTs can reduce participation barriers. The agency has issued draft guidance to help sponsors design and execute high quality decentralized trials that meet all regulatory requirements for safety and data integrity.